Lonza Strengthens Pharma, Biotech and Nutrition Offerings with Aligned Structure and New Executive Committee Appointment
Alignment of the scope of segments to further strengthen collaboration and leverage synergies Pharma & Biotech and Consu…
Alignment of the scope of segments to further strengthen collaboration and leverage synergies Pharma & Biotech and Consu…
The number of hip prostheses in the EU has risen steadily over the past ten years – most notably in Austria and Germany…
. - Konzernumsatz +13,2% auf 1,57 Mrd. Euro; Ertrag1) steigt überproportional um 14,7% auf 405,0 Mio. Euro - Dividendenv…
Richard Ridinger to retire Marc Funk appointed CEO Handover as of 1 March 2019 Lonza announced today that Richard Ridi…
Lonza delivered its Full-Year 2018 results with sales of CHF 5.5 billion at a record 27.3% CORE EBITDA margin for Lo…
Konzernumsatz nach vorläufigen Zahlen +13,2% auf 1,57 Mrd. Euro; Ertrag1) steigt überproportional um 14,7% auf 405,0 Mio…
Lonza announced today that Standard & Poor's (S&P) assigned a BBB+ credit rating with stable outlook to Lonza. Lonza con…
Fridtjof Helemann will leave the company on 31 March 2019, upon reaching retirement age. He has been Chief Human Resourc…
Lonza today is publishing unaudited Full-Year 2017 information excluding the Water Care business and taking into conside…
. New biologics facility, scheduled to be operational in 2020, will provide development and manufacturing facilities f…